CASI CASI Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CASI

Price (delayed)

$2.3

Market cap

$30.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$32.58M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
CASI Pharmaceuticals's net income has increased by 34% YoY and by 33% from the previous quarter
CASI's EPS is up by 33% since the previous quarter and by 33% year-on-year
The equity has declined by 46% year-on-year and by 16% since the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 39% from the previous quarter and by 35% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.casipharmaceuticals.com/
Peers: RGEN CRIS NBIX AMGN

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
13.38M
Market cap
$30.77M
Enterprise value
$32.58M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.27
Price to sales (P/S)
0.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.96
Earnings
Revenue
$33.88M
EBIT
-$27.02M
EBITDA
-$22.29M
Free cash flow
-$22.21M
Per share
EPS
-$2.02
Free cash flow per share
-$1.66
Book value per share
$1.81
Revenue per share
$2.54
TBVPS
$5.5
Balance sheet
Total assets
$75.27M
Total liabilities
$51.1M
Debt
$18.9M
Equity
$24.17M
Working capital
$42.62M
Liquidity
Debt to equity
0.78
Current ratio
3.55
Quick ratio
2.45
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-65.8%
Gross margin
59.2%
Net margin
-79.5%
Operating margin
-74.6%
Efficiency
Return on assets
-34.2%
Return on equity
-86.4%
Return on invested capital
-52.4%
Return on capital employed
-46.2%
Return on sales
-79.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
-5.74%
1 week
2.68%
1 month
-23.08%
1 year
-22.56%
YTD
-67.88%
QTD
-36.29%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$33.88M
Gross profit
$20.05M
Operating income
-$25.28M
Net income
-$26.94M
Gross margin
59.2%
Net margin
-79.5%
CASI Pharmaceuticals's net income has increased by 34% YoY and by 33% from the previous quarter
The operating income has grown by 33% from the previous quarter and by 32% YoY
CASI's gross profit is down by 26% YoY and by 26% QoQ
CASI's revenue is down by 21% YoY and by 20% QoQ

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.27
P/S
0.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.96
CASI's EPS is up by 33% since the previous quarter and by 33% year-on-year
The equity has declined by 46% year-on-year and by 16% since the previous quarter
The stock's P/B is 45% below its 5-year quarterly average of 2.3 and 25% below its last 4 quarters average of 1.7
CASI's P/S is 95% below its 5-year quarterly average of 18.0 and 30% below its last 4 quarters average of 1.3
CASI's revenue is down by 21% YoY and by 20% QoQ

Efficiency

How efficient is CASI Pharmaceuticals business performance
CASI's ROIC is up by 39% from the previous quarter and by 18% YoY
The return on equity has declined by 31% year-on-year but it is up by 22% since the previous quarter
The ROA has grown by 29% from the previous quarter
CASI's return on sales is up by 12% since the previous quarter and by 12% year-on-year

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
The total assets is 47% greater than the total liabilities
CASI's total liabilities has soared by 115% from the previous quarter and by 74% YoY
CASI Pharmaceuticals's quick ratio has decreased by 39% from the previous quarter and by 35% YoY
The debt is 22% smaller than the equity
The equity has declined by 46% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.